Tmunity Therapeutics Revenue and Competitors

Location

$230M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Tmunity Therapeutics's estimated annual revenue is currently $2.6M per year.(i)
  • Tmunity Therapeutics received $35.0M in venture funding in April 2018.
  • Tmunity Therapeutics's estimated revenue per employee is $77,500
  • Tmunity Therapeutics's total funding is $230M.

Employee Data

  • Tmunity Therapeutics has 33 Employees.(i)
  • Tmunity Therapeutics grew their employee count by -41% last year.

Tmunity Therapeutics's People

NameTitleEmail/Phone
1
Executive Director, Quality AssuranceReveal Email/Phone
2
Head Strategic Partnerships; Executive Director Corporate DevelopmentReveal Email/Phone
3
EVP & Chief Business OfficerReveal Email/Phone
4
Manager MSATReveal Email/Phone
5
Executive Assistant Office ManagerReveal Email/Phone
6
Project ManagerReveal Email/Phone
7
Senior Clinical Trial ManagerReveal Email/Phone
8
Associate Process Development Scientist - EngineeringReveal Email/Phone
9
Associate Process EngineerReveal Email/Phone
10
Clinical Research AssociateReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.6M100%N/AN/A
#2
$4M2613%N/AN/A
#3
$0.9M6-14%N/AN/A
#4
$1.1M70%N/AN/A
#5
$10.9M703%N/AN/A
#6
$0.7M929%N/AN/A
#7
$4M26-16%N/AN/A
#8
$1.7M1122%N/AN/A
#9
$7.6M492%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is Tmunity Therapeutics?

Our vision is to become the leading innovative global life-sciences company that unlocks the potential of T-cell biology and combines it with the power of T-cell engineering excellence to provide cures for patients. Through our model of seamless and rapid integration of research, translational medicine, manufacturing science, clinical development and customer-centric approaches, we will design and deliver enhanced state-of-the-art solutions for patients in a host of disease areas using Chimeric Antigen Receptors (CARs), Gene edited T-Cells, T regulatory cells (Treg), and engineered T Cell Receptors (TCRs)

keywords:N/A

$230M

Total Funding

33

Number of Employees

$2.6M

Revenue (est)

-41%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Tmunity Therapeutics News

2022-04-20 - In wake of IL-2 shutdown, Nektar lets go of 500+ staffers as it ...

So as Nektar Therapeutics prepares for a future without it, ... several blood cancers — into solid tumors took a hit last year when Tmunity,...

2022-04-19 - Astellas, Tmunity, underscore rocky terrain of CAR-T and gene ...

In addition to ICANS, another known side effect of CAR-T therapies is cytokine release syndrome, which caused setbacks in several clinical...

2022-02-22 - CEO of Philadelphia cell therapy firm Tmunity departs for new job in ...

Tmunity, which is based in Philadelphia, has its own manufacturing operations in East Norriton. Tmunity's founders include June and fellow Penn...

2019-10-31 - Tmunity Therapeutics Raises $75 Million Series B

PHILADELPHIA--(BUSINESS WIRE)--Tmunity Therapeutics, in pursuit of its vision to save and improve lives by delivering the full potential of next-generation T-cell immunotherapy, closed a $75 million Series B financing. The financing was led by Andreessen Horowitz (also known as "a16z"), a ventur ...

2019-10-31 - Tmunity Secures $75M in Series B Financing

Tmunity Therapeutics, a Philadelphia, PA-based T-cell immunotherapy company, closed a $75m Series B financing. The round was led by Andreessen Horowitz with participation from a16z’s Cultural Leadership Fund, Westlake Village BioPartners, Gilead Sciences, The University of Pennsylvania, Be The ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$5.4M333%N/A
#2
$3.8M33N/AN/A
#3
$3.8M33N/AN/A
#4
$5.4M3310%N/A
#5
$6.6M330%N/A

Tmunity Therapeutics Funding

DateAmountRoundLead InvestorsReference
2018-01-24$100.0MAMultipleArticle
2018-04-20$35.0MAKleiner PerkinsArticle